HC Wainwright & Co. Maintains Buy on Akero Therapeutics, Lowers Price Target to $40
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Ed Arce maintains a 'Buy' rating on Akero Therapeutics (NASDAQ:AKRO) but lowers the price target from $64 to $40.
October 11, 2023 | 4:31 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Akero Therapeutics' price target has been lowered from $64 to $40 by HC Wainwright & Co., though the 'Buy' rating is maintained.
The lowering of the price target for Akero Therapeutics by HC Wainwright & Co. could potentially lead to a short-term negative impact on the stock price. However, the maintained 'Buy' rating indicates that the analyst still sees potential in the company's stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100